HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Seaport analyst Kenneth Zener adjusts his stance on homebuilding stocks, downgrading key players due to a cautious outlook for FY24. With recession concerns lingering, Zener anticipates potential challenges, emphasizing the risk of anticipated tailwinds transforming into headwinds. Builder margins are expected to stabilize, influenced by diminishing past incentives, counteracted by rising input costs.
Fiverr's stock rises as Goldman Sachs upgrades it to Buy with a $43 target, citing revenue re-acceleration and AI-driven product innovation. Eric Sheridan highlights Fiverr's progress in marketing efficiency and expansion in personalized offerings.